Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LTRN 
Lantern Pharma Inc (LTRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: LTRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.83% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.25M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 2 | Beta 1.57 | 52 Weeks Range 2.55 - 6.12 | Updated Date 11/4/2025 |
52 Weeks Range 2.55 - 6.12 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.44 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.35% | Return on Equity (TTM) -88.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27656921 | Price to Sales(TTM) - |
Enterprise Value 27656921 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 10799417 | Shares Floating 8202373 |
Shares Outstanding 10799417 | Shares Floating 8202373 | ||
Percent Insiders 14.09 | Percent Institutions 20.96 |
Upturn AI SWOT
Lantern Pharma Inc
Company Overview
History and Background
Lantern Pharma Inc. was founded in 2013. The company is focused on leveraging artificial intelligence (AI) and machine learning to rescue, revitalize and develop precision oncology therapeutics. Lantern Pharma has acquired many different drugs to use for cancer treatment.
Core Business Areas
- Drug Development: Lantern Pharma focuses on developing oncology therapeutics using its AI platform, RADR, to identify and validate drug candidates.
- AI-Driven Drug Discovery: Lantern Pharma uses AI and machine learning to predict drug response and patient stratification, optimizing clinical trials.
Leadership and Structure
Panna Sharma serves as the CEO and President. The organizational structure is typical of a biotech firm, with departments focused on research, development, clinical trials, and AI/data science.
Top Products and Market Share
Key Offerings
- LP-100 (Tavocepient): A small molecule drug candidate being developed for various cancers. It is in the clinical trial phase. Competitors developing similar oncology drugs include large pharmaceutical companies like Pfizer, Novartis, and Merck.
- Market Share (%): Market share is not yet applicable because it is in clinical trial phase and has not generated revenue
- LP-300: An Aza-CdR compound being developed for never smokers with NSCLC after failing platinum-based therapy. A Phase 2 trial has shown positive signals and LP-300 is expected to be moved forward for FDA review. Competitors developing similar oncology drugs include large pharmaceutical companies like Pfizer, Novartis, and Merck.
- Market Share (%): Market share is not yet applicable because it is in clinical trial phase and has not generated revenue
Market Dynamics
Industry Overview
The oncology therapeutics industry is characterized by high growth, technological innovation, and intense competition. The use of AI is increasingly prevalent for drug discovery and development.
Positioning
Lantern Pharma is positioned as an AI-driven precision oncology company. Its competitive advantage lies in its RADR platform, which aims to improve drug development efficiency and patient outcomes.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Lantern Pharma is targeting specific subsets of cancers where its AI platform can provide a competitive edge.
Upturn SWOT Analysis
Strengths
- Proprietary AI platform (RADR)
- Focus on precision oncology
- Experienced leadership team
- Diversified pipeline of drug candidates
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Drug development inherently involves risk
- Market share is not yet applicable because it is in clinical trial phase and has not generated revenue
- High cash burn rate
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion of RADR platform to other therapeutic areas
- Positive clinical trial results
- Accelerated regulatory pathways for oncology drugs
Threats
- Competition from larger pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- NVS
- PFE
Competitive Landscape
Lantern Pharma faces competition from larger pharmaceutical and biotech companies with greater resources and established pipelines. Lantern Pharma's advantage is in AI-driven drug discovery.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D investments and strategic acquisitions of assets, rather than revenue generation.
Future Projections: Future growth is dependent on successful clinical trials and commercialization of drug candidates. Analyst estimates vary based on pipeline progress.
Recent Initiatives: Recent initiatives include advancing clinical trials for LP-100 and LP-300, expanding RADR platform capabilities, and forming strategic collaborations.
Summary
Lantern Pharma is an AI-driven precision oncology company focused on developing innovative cancer therapies. While its AI platform holds promise, it faces significant competition from established pharmaceutical companies. The success of its pipeline and its ability to secure partnerships are crucial for future growth. Financial resources need close monitoring due to high cash burn.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Lantern Pharma Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The pharmaceutical industry is inherently risky, and past performance is not indicative of future results. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantern Pharma Inc
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2020-06-11 | President, CEO & Director Mr. Panna Sharma | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.lanternpharma.com |
Full time employees 24 | Website https://www.lanternpharma.com | ||
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.